[1] Lerche O. Statins are ‘SAFE’: Life-saving benefits of cholesterol-busting drugs outweigh risks. Express.co.uk. 9 September 2016. Available at: http://www.express.co.uk/life-style/health/708590/statins-cholesterol-safe-side-effects-benefits (accessed 22 June 2017)
[2] Dunlevy S. ABC’s Catalyst program on cholesterol will kill people: Dr Norman Swan. News.com.au (Australia). 5 November 2013. Available at: http://www.news.com.au/lifestyle/health/abcs-catalyst-program-on-cholesterol-will-kill-people-dr-norman-swan/news-story/953236029d657bfd0cdf38326788efac (accessed 22 June 2017)
[3] Daniels SR, Pratt CA, Hayman LL. Reduction of risk for cardiovascular disease in children and adolescents. Circulation 2011;124(15):1673–86. doi: 10.1161/CIRCULATIONAHA.110.016170
[4] Lundh A, Lexchin J, Mintzes B et al. Industry sponsorship and research outcome. Cochrane Database Syst Rev 2017;2:MR000033.
[5] Diamond DA, Ravnskov U. How statistical deception created the appearance that statins are safe and effective in primary and secondary prevention of cardiovascular disease. Exp Rev Clin Pharmacol 2015;8(2):201–10. doi: 10.1586/17512433.2015.1012494
[6] De Lorgeril M, Rabaeus M. Beyond confusion and controversy, can we evaluate the real efficacy and safety of cholesterol-lowering with statins?J Controversies Biomed Res 2015;1(1):67–92. doi: 10.15586/jcbmr.2015.11
[7] Collins R, Reith C, Emberson Jet al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 2016;388:2532–61. doi: 10.1016/S0140-6736(16)31357-5
[8] DuBroff R. Cholesterol paradox: a correlate does not a surrogate make. Evid Based Med 2017;22(1):15–9. doi: 10.1136/ebmed-2016-110602
[9] Vancheri F, Backlund L, Strender L et al. Time trends in statin utilisation and coronary mortality in Western European countries. BMJ Open 2016;6(3):e010500. doi: 10.1136/bmjopen-2015-010500
[10] Han BH, Sutin D, Williamson JDet al. Cardiovascular prevention among older adults: the ALLHAT-LLT randomized clinical trial. JAMA Intern Med 2017;177(7):955–65. doi: 10.1001/jamainternmed.2017.1442
[11] Kristensen ML, Christensen PM, Hallas J. The effect of statins on average survival in randomised trials, an analysis of end point postponement. BMJ Open 2015;5:e007118. doi: 10.1136/bmjopen-2014-007118
[12] Sabatine MS, Giugliano RP, Keech AC et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 376(18):1713–22. doi: 10.1056/NEJMoa161566
[13] Bodkin H, Stoneman J. NHS wasting tens of thousands a year on ‘wonder’ drug for stroke and heart attacks which does not work, experts claim. The Telegraph (UK). 6 May 2017. Available at: http://www.telegraph.co.uk/news/2017/05/06/nhs-wasting-tens-thousands-year-wonder-drug-stroke-heart-attacks/ (accessed 22 June 2017)
[14] de Lorgeril M, Renaud S, Mamelle N et al. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet 2015;343(8911):1454–9. PMID: 7911176
[15] Rabaeus M, Nguyen PV, de Lorgeril M. Recent flaws in Evidence Based Medicine: statin effects in primary prevention and consequences of suspending the treatment. J Controversies Biomed Res 2017;3(1):1–10. doi: 10.15586/jcbmr.2017.18
[16] Wang H, Liddell CA, Coates MM et al. Global, regional, and national levels of neonatal, infant, and under-5 mortality during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014;384:957–79. doi: 10.1016/S0140-6736(14)60497-9
[17] Basu S, Yoffe P, Hills N et al. The relationship of sugar to population-level diabetes prevalence: an econometric analysis of repeated cross-sectional data. PLoS One 2013;8(2):e57873. doi: 10.1371/journal.pone.0057873
[18] Sepúlveda J, Murray C. The state of global health in 2014. Science 2014;345(6202):1275-8. doi: 10.1126/science.1257099
[19] Chan JM, Rimm EB, Colditz GA et al. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care 1994;17:961–9. PMID: 7988316
[20] McLaughlin T, Abbasi F, Cheal K et al. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Int Med 2003;139:802–9. PMID: 14623617
[21] Chen DL, Liess C, Poljak A et al. Phenotypic characterization of insulin-resistant and insulin-sensitive obesity. J Clin Endocrinol Metab. 2015;100(11):4082–91. doi: 10.1210/jc.2015-2712
[22] Abbasi F, Chu JW, Lamendola C et al. Discrimination between obesity and insulin resistance in the relationship with adiponectin. Diabetes 2004;53(3):585–90. PMID: 14988241
[23] Voulgari C, Tentolouris N, Dilaveris P et al. Increased heart failure risk in normal-weight people with metabolic syndrome compared with metabolically healthy obese individuals. J Am Coll Cardiol 2011;58(13):1343–50. doi: 10.1016/j.jacc.2011.04.047
[24] Menke A, Casagrande S, Geiss L et al. Prevalence of and trends in diabetes among adults in the United States, 1988–2012. JAMA 2015;314(10):1052–62. doi:10.1001/jama.2015.10029
[25] Chehab FF. Obesity and lipodystrophy — where do the circles intersect? Endocrinology 2008;149(3):925–34. doi: 10.1210/en.2007-1355
[26] Bremer AA, Mietus-Snyder ML, Lustig RH. Toward a unifying hypothesis of metabolic syndrome. Pediatrics 2012;129(3):557–70. doi: 10.1542/peds.2011-2912
[27] Lustig RH, Mulligan K, Noworolski SM et al. Isocaloric fructose restriction and metabolic improvement in children with obesity and metabolic syndrome. Obesity 2016;24(2):453–60. doi: 10.1002/oby.21371
[28] Gugliucci A, Lustig RH, Caccavello R et al. Short-term isocaloric fructose restriction lowers apoC-III levels and yields less atherogenic lipoprotein profiles in children with obesity and metabolic syndrome. Atherosclerosis 2016;253:171–7.doi: 10.1016/j.atherosclerosis.2016.06.048
[29] Lucan SC, DiNicolantonio JJ. How calorie-focused thinking about obesity and related diseases may mislead and harm public health. An alternative. Public Health Nutr 2015;18(4):571–81. doi: 10.1017/S1368980014002559
[30] Haas JT, Biddinger SB. Dissecting the role of insulin resistance in the metabolic syndrome. Curr Opin Lipidol 2009;20(3):206–10. doi: 10.1097/MOL.0b013e32832b2024
[31] Yip J, Facchini FS, Reaven GM. Resistance to insulin-mediated glucose disposal as a predictor of cardiovascular disease. J Clin Endocrinol Metab 1998;83(8):2773–6. doi: 10.1210/jcem.83.8.5005
[32] Arnold SV, Lipska KJ, Li Y et al. The reliability and prognosis of in-hospital diagnosis of metabolic syndrome in the setting of acute myocardial infarction. J Am Coll Cardiol 2013;8(8):704–8. doi: 10.1016/j.jacc.2013.02.062
[33] Eddy D, Schlessinger L, Kahn R et al. Relationship of insulin resistance and related metabolic variables to coronary artery disease: a mathematical analysis. Diabetes Care 2009;32(2):361–6. doi: 10.2337/dc08-0854
[34] The Action to Control Cardiovascular Risk in Diabetes Study Group. Gerstein HC, Miller ME, Byington RP et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545–59. doi: 10.1001/jamainternmed.2017.1442
[35] Schwarz JM Noworolski SM, Gugliucci A et al. Effects of dietary fructose restriction on liver fat, de novo lipogenesis, and insulin kinetics in children with obesity. Gastroenterology 2017;pii:S0016–5085(17)35685–8. doi: 10.1053/j.gastro.2017.05.043
[36] Snorgaard O, Poulsen GM, Andersen HK et al. Systematic review and meta-analysis of dietary carbohydrate restriction in patients with type 2 diabetes.BMJ Open Diabetes Res Care 2017;5(1):e000354. doi: 10.1136/bmjdrc-2016-000354
[37] Sacks FM, Lichtenstein AH, Wu JHY et al. Dietary fats and cardiovascular disease: a Presidential Advisory from the American Heart Association. Circulation 15 June 2017. doi: 10.1161/CIR.0000000000000510
[38] Albert BB, Derraik JG, Brennan CM. Higher omega-3 index is associated with increased insulin sensitivity and more favourablemetabolic profile in middle-aged overweight men. Sci Rep 2014;4:6697. doi: 10.1038/srep06697
[39] Malhotra A, Redberg RF, Meier P. Saturated fat does not clog the arteries: coronary heart disease is a chronic inflammatory condition, the risk of which can be effectively reduced from healthy lifestyle interventions. Br J Sports Med doi: 10.1136/bjsports-2016-097285
[40] Wen CP, Wai JP TM, Yang Y et al. Minimum amount of physical activity for reduced mortality and extended life expectancy: a prospective cohort study. Lancet 2011;378:1244-53. doi: 10.1016/S0140-6736(11)60749-6
[41] Naci H, Ioannidis JPA. Comparative effectiveness of exercise and drug interventions on mortality outcomes: metaepidemiological study. BMJ 2013;347:f5577. doi: 10.1136/bmj.f5577
[42] Vreman RA, Goodell AJ, Rodriguez LA et al. Health and economic benefits of reducing sugar intake in the United States, including effects via non-alcoholic fatty liver disease: a microsimulation model. BMJ Open 2017 (in press)